Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Casein kinase inhibitor A51 is an inhibitor of casein kinase 1α (CK1α).1 It binds to CK1α, CK1δ, and CK1ε (Kds = 5.3, 1.8, and 4.4 nM, respectively) and reduces phosphorylation of β-catenin at serine 45, a site phosphorylated specifically by CK1α, when used at a concentration of 1 µM. Casein kinase inhibitor A51 (27 nM) inhibits the proliferation of bone marrow cells isolated from mice with acute myeloid leukemia (AML) driven by the oncogenic fusion protein MLL-AF9. It rapidly increases intratumoral levels of p53 and induces intratumoral apoptosis in a murine model of MLL-AF9-driven AML. Casein kinase inhibitor A51 (5 mg/kg per day) also increases survival and eradicates signs of disease in the same model over five months.
WARNING This product is not for human or veterinary use.
1. Small molecules co-